Multiple Sclerosis Trial, Recruiting (NCT06780150)

Multiple Sclerosis Trial, Recruiting NCT06780150 Sponsor: Hoffmann-La Roche Condition: Multiple Sclerosis

Printed from Voxsanity (voxsanity.com.au) — NCT06780150 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Multiple Sclerosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with multiple sclerosis (MS), either the relapsing form or the primary progressive form, based on a specific standard set of diagnostic guidelines from 2017 (called the McDonald criteria)
People who are starting ocrelizumab SC (given under the skin) for the first time as part of their MS treatment, for any reason, in line with how the medication is approved for use in their country

Who may not be able to join:

People who are currently taking part in another clinical trial testing a disease-modifying treatment for MS
People who have previously or are currently taking part in either the CONFIDENCE or MoOzaRt studies at the same trial location
People who have previously been treated with rituximab (also known as MabThera®) or ublituximab (also known as Briumvi®)
People with a severe psychiatric condition
People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 16 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Clinical Trials, Hoffmann-La Roche

Phone: 888-662-6728 (U.S. Only)

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06780150

Sponsor: Hoffmann-La Roche

Phase: Not Applicable

Status: Recruiting

Condition: Multiple Sclerosis

Trial contact: 888-662-6728 (U.S. Only)

More information: https://clinicaltrials.gov/study/NCT06780150

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with multiple sclerosis (MS), either the relapsing form or the primary progressive form, based on a specific standard set of diagnostic guidelines from 2017 (called the McDonald criteria)
People who are starting ocrelizumab SC (given under the skin) for the first time as part of their MS treatment, for any reason, in line with how the medication is approved for use in their country

Who may not be able to join:

People who are currently taking part in another clinical trial testing a disease-modifying treatment for MS
People who have previously or are currently taking part in either the CONFIDENCE or MoOzaRt studies at the same trial location
People who have previously been treated with rituximab (also known as MabThera®) or ublituximab (also known as Briumvi®)
People with a severe psychiatric condition
People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Hoffmann-La Roche

Registry

ClinicalTrials.gov

Start date

26 September 2024

Est. completion

31 March 2028

Where this trial is recruiting

🇩🇪 Germany 🇨🇭 Switzerland

Primary endpoints

Number of Participants by Their Level of Satisfaction With Ocrelizumab SC After 12 Months Assessed Using TASQ-SC

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov